# Parapneumonic Effusion Drainage Criteria

Drain parapneumonic effusions when pleural fluid is purulent, microbiologically positive, markedly acidotic, or anatomically large or loculated. Use immediate blood-gas pH measurement after diagnostic thoracentesis to distinguish patients likely to resolve with antibiotics from those requiring image-guided tube drainage and escalation.

**Clinical question:** Which clinical, imaging, and pleural fluid findings require drainage of a parapneumonic effusion?

Updated: 2026-09-15T18:12:51.168009+00:00

## What matters in practice
- Frank pus or organisms on pleural-fluid Gram stain or culture establishes pleural infection and requires formal pleural drainage. [11]
- If aspiration is not purulent, measure pleural-fluid pH immediately; pH ≤7.15 indicates high risk of complicated parapneumonic effusion and supports intercostal drainage. [2]
- For pleural-fluid pH 7.16-7.38, drainage risk declines as pH rises, particularly above 7.22; integrate glucose, LDH, imaging, and the clinical course rather than using one borderline result alone. [2]
- Loculation on ultrasound or chest radiography and a large collection increase the likelihood of drainage failure and support early tube drainage. [10][12]
- After inadequate tube drainage with residual infected collection, combined intrapleural alteplase 10 mg plus DNase 5 mg twice daily for 3 days is an evidence-based rescue approach; persistent sepsis or inadequate source control requires procedural escalation. [22][23][24]

## Findings that mandate pleural drainage

Treat pneumonia and achieve pleural source control in parallel.

Proceed to image-guided intercostal drainage when diagnostic thoracentesis yields frankly purulent fluid or when pleural-fluid Gram stain or culture identifies organisms. These findings define infected pleural fluid that is not expected to resolve with antibiotics alone. [11]

Drain a nonpurulent parapneumonic effusion when pleural-fluid pH is <7.20 in an appropriate infectious presentation. A pleural glucose <60 mg/dL and LDH >1,000 IU/L are corroborating markers of complicated infection, but pH is the preferred initial biochemical discriminator. [11][12][18]

Do not rely on biochemical thresholds to defer drainage when imaging shows a large effusion or loculations, or when the patient has ongoing sepsis with a pleural collection. Radiographic size and loculation are guideline-recognized features of complicated parapneumonic effusion and are associated with poorer outcomes after tube thoracostomy. [10][12]
- Frank pus: insert a pleural drain; do not await culture results. [11]
- Positive Gram stain or culture: drain the pleural space even if fluid is not grossly purulent. [11]
- pH <7.20: manage as a complicated parapneumonic effusion and drain, provided the clinical context is pleural infection. [11][12]
- Loculated or large effusion: favor early image-guided tube drainage, especially with persistent fever, inflammatory markers, or respiratory compromise. [10][12]

*Drainage triggers in suspected parapneumonic pleural infection. [2][10][11][12]*

| Finding at aspiration or imaging | Interpretation | Next action |
| --- | --- | --- |
| Frankly purulent pleural fluid [11] | Empyema / infected pleural space [11] | Insert image-guided intercostal drain. [11] |
| Positive Gram stain or pleural-fluid culture [11] | Microbiologically proven pleural infection [11] | Drain the infected collection. [11] |
| Pleural-fluid pH ≤7.15 [2] | High likelihood of complicated course [2] | Intercostal drainage is indicated. [2] |
| Pleural-fluid pH 7.16-7.21 [2] | Meaningful risk of complicated pleural infection [2] | Use glucose, LDH, imaging, and clinical trajectory to determine drainage; favor drainage when additional adverse features are present. [2][12] |
| Pleural-fluid pH 7.22-7.38 [2] | Risk decreases as pH rises, especially above 7.22 [2] | Do not drain solely for pH; assess for loculation, size, microbiology, and clinical deterioration. [2][12] |
| Pleural-fluid pH >7.38 [2] | Very low risk of complicated parapneumonic effusion [2] | Antibiotics and clinical-radiographic follow-up are generally appropriate unless another drainage trigger is present. [2] |
| Loculation or a large pleural collection [10][12] | Impaired spontaneous or catheter drainage; increased risk of poor outcome [10] | Arrange image-guided chest drainage early. [10][12] |

## Obtain pleural-fluid results that change the drainage decision

Sample pleural fluid promptly when pneumonia is accompanied by a clinically significant effusion.

Use thoracic ultrasonography before aspiration or drain placement to confirm fluid, estimate volume, distinguish free-flowing from loculated fluid, assess echogenicity, and select a safe drainage site. Ultrasound is particularly useful when chest radiography shows hemithorax opacification and can be performed at the bedside. [1]

If fluid is not pus, collect pleural fluid for immediate pH measurement in an appropriate blood-gas syringe without air contamination and analyze it promptly on a point-of-care blood-gas analyzer. Delayed analysis or air exposure can make pH unreliable and can misclassify a patient near the drainage threshold. [2][9]

Send Gram stain and culture with pH, glucose, and LDH. Culture sensitivity is limited: standard microbiologic practice identified plausible organisms in only 16% to 19% of pleural infections in reported cohorts, so a negative culture does not override purulence, low pH, loculation, or a deteriorating clinical course. [9]
- Use pH as the primary biochemical drainage test when fluid is not purulent. [2][18]
- If an immediate accurate pH is unavailable, pleural glucose 4.0 mmol/L or lower in a nondiabetic patient indicates a moderate-to-high likelihood of complicated parapneumonic effusion. [2]
- Interpret glucose cautiously in diabetes because severe hyperglycemia can leave pleural-fluid glucose above usual drainage cutoffs despite pleural infection. [12]
- A normal pH does not categorically exclude infection; rare Proteus mirabilis empyema may have an elevated pleural-fluid pH. [11]

### How to interpret borderline biochemistry

For pH 7.16-7.38, do not use a single cutoff mechanically. The probability of complicated parapneumonic effusion falls with increasing pH, especially once pH exceeds 7.22, while pleural glucose and LDH are less accurate than pH as independent initial predictors. [2]
- Pleural glucose <35 mg/dL and LDH >1,000 IU/L support complicated infection when pH is unavailable, questionable, or borderline. [11]
- Pleural CRP >100 mg/L or serum CRP >200 mg/L may improve prediction when combined with pH or glucose, but other proposed pleural biomarkers remain investigational. [12]

*Pleural-fluid testing and interpretation for drainage decisions. [2][9][11][12]*

| Test | Actionable result | Clinical use |
| --- | --- | --- |
| Gross appearance [11] | Frank pus [11] | Diagnostic of empyema; drain immediately. [11] |
| Gram stain or culture [11] | Any organism detected [11] | Confirms pleural infection and mandates drainage. [11] |
| pH, measured immediately [2][9] | ≤7.15: high risk; >7.38: very low risk [2] | Primary biochemical discriminator for intercostal drainage. [2] |
| Glucose [2][11] | ≤4.0 mmol/L in nondiabetic patient; <35 mg/dL strongly supportive [2][11] | Use when pH cannot be obtained accurately or as corroboration for a borderline pH. [2] |
| LDH [11][12] | >1,000 IU/L [11] | Supports complicated infection but should not independently determine drainage. [12][18] |

## Use ultrasound to select drainage and CT to investigate failure or alternative pathology

Imaging determines access, complexity, and the need to look beyond uncomplicated pleural infection.

Use thoracic ultrasound to map septations and locules and to guide thoracentesis or chest-drain insertion. Ultrasound identifies free versus loculated fluid and pleural thickening, but it does not reliably stage pleural infection; do not withhold drainage because ultrasound cannot distinguish fibrinopurulent from organizing disease. [1]

Contrast-enhanced chest CT is most useful when initial aspiration fails, tube drainage is inadequate, medical management is failing, or an endobronchial obstruction, lung abscess, mediastinal process, or other parenchymal abnormality must be assessed. CT can delineate loculated fluid and pleural contrast enhancement may improve detection of complicated parapneumonic effusion. [1][2]

A small-bore 10-14 F catheter is considered adequate for most complicated pleural infections in BTS guidance. If using a small-bore flexible catheter, flush with 20-30 mL saline every 6 hours to reduce obstruction risk. [5]
- Choose the drain target with ultrasound rather than relying on chest radiography alone. [1]
- Obtain contrast-enhanced CT when persistent residual fluid or failure to improve raises concern for an undrained locule, abscess, or obstructing lesion. [1]
- Recognize that collections occupying >40% of the hemithorax may be more likely to require surgery. [10]

*Imaging findings that alter drainage management. [1][2][10]*

| Imaging result | What it changes | Action |
| --- | --- | --- |
| Free pleural fluid on ultrasound [1] | Identifies an accessible target for aspiration or catheter placement [1] | Perform ultrasound-guided diagnostic aspiration; drain if fluid or clinical criteria are met. [1][2][11] |
| Septated or loculated fluid [1][10] | Signals impaired drainage and poorer tube-thoracostomy outcome [10] | Place image-guided drain; reassess promptly for residual locules and escalation. [1][10] |
| Pleural contrast enhancement on CT [2] | May improve detection of complicated parapneumonic effusion [2] | Integrate with pleural-fluid findings and clinical sepsis when deciding to drain. [2] |
| Failure of aspiration or medical management [1] | Raises concern for inaccessible locule, abscess, obstruction, or alternative pathology [1] | Obtain contrast-enhanced CT and plan additional drainage or procedural management. [1] |

## Escalate when tube drainage leaves an infected residual collection

A drain is not definitive source control unless the collection resolves and the patient improves.

After catheter placement, reassess drainage output, residual pleural collection on imaging, and clinical response. Persistent infected fluid due to loculations, septations, or viscous pus is a drainage failure pattern; approximately 30% of cases may be difficult to evacuate for these anatomic reasons. [21]

When initial chest-tube drainage has ceased but an infected residual collection remains, consider combined intrapleural alteplase and DNase. The MIST-2 regimen was alteplase 10 mg plus DNase 5 mg, administered intrapleurally twice daily for 3 days, for 12 total instillations. Combination therapy improved drainage and has been used as rescue treatment after antibiotics and thoracostomy drainage fail to achieve adequate clearance. [22][23][24]

Do not substitute single-agent fibrinolytic therapy for the combination regimen on the basis of the available comparative evidence. Combination tPA/DNase has a recognized bleeding risk, including pleural hemorrhage and hemoptysis; weigh this risk before use and involve procedural teams early when a patient has a persistent collection or cannot tolerate intrapleural therapy. [22]
- Residual loculated collection after drain output stops: evaluate for intrapleural tPA/DNase or procedural clearance rather than simply leaving an ineffective catheter in place. [22][24]
- Persistent inadequate clearance despite drainage-based therapy: obtain surgical assessment for VATS drainage or decortication. [4][21]
- A large collection, multiloculation, or persistent sepsis should lower the threshold for early procedural escalation. [10][21]

### Role of surgery

VATS is an alternative source-control strategy for complex parapneumonic effusion and empyema, particularly when tube drainage with or without intrapleural therapy does not achieve clearance. Direct comparisons of first-line VATS with ultrasound-guided catheter drainage plus alteplase/DNase remain an active area of study, so the practical decision should prioritize timely clearance of persistent infected pleural space. [4][21]
- Consider surgery early for inadequately drained multiloculated empyema; space deloculation is described at 1-2 weeks in this setting. [20]
- Decortication may be required for unresolved empyema or organizing pleural restriction; procedure-related harms include pain, recurrence, prolonged hospitalization, chest-organ injury, diaphragmatic paralysis, and rib fracture. [17][20]

*Escalation after initial chest-tube drainage. [4][20][21][22][23][24]*

| Post-drain finding | Likely problem | Escalation |
| --- | --- | --- |
| Output ceases with residual infected collection [22] | Loculation, septation, or viscous fluid prevents evacuation [21] | Consider intrapleural alteplase 10 mg plus DNase 5 mg twice daily for 3 days. [22][23] |
| Persistent collection or clinical nonresponse after drainage-based therapy [4][21] | Inadequate source control [21] | Obtain thoracic surgical assessment for VATS drainage or decortication. [4][20] |
| Large collection occupying >40% of hemithorax [10] | Higher likelihood of needing surgery [10] | Plan close reassessment and early procedural escalation if drainage is incomplete. [10] |

## Avoid common errors in deciding against drainage

Low-risk biochemistry is reassuring only when the broader infectious assessment is concordant.

Do not classify every pneumonia-associated effusion as requiring a drain. Most sterile simple parapneumonic effusions resolve with antibiotic treatment alone; the drainage decision depends on evidence of pleural infection, adverse pleural-fluid chemistry, large volume, loculation, or failure to improve. [8][12]

Do not use a negative culture to label a patient uncomplicated, and do not use a single low glucose value without context. Pleural cultures are frequently negative, glucose is affected by diabetes-related hyperglycemia, and pH remains the more accurate independent initial predictor of complicated parapneumonic effusion. [2][9][12][18]

When pH is high but clinical concern remains substantial, re-evaluate sampling quality, ultrasound anatomy, and alternative explanations for the collection. Rare Proteus empyema can produce an elevated pH, while loculated fluid may require direct targeting of the relevant pocket for representative sampling and drainage planning. [1][11]
- Antibiotics alone are reasonable only when there is no purulence, no microbiologic proof of pleural infection, no adverse biochemical or anatomic feature, and the patient improves clinically. [8][11][12]
- A pH >7.38 indicates very low risk of complicated parapneumonic effusion, not an absolute exclusion of pleural infection. [2][11]
- Use CT selectively for failed aspiration or failing medical management, not as a routine substitute for ultrasound-guided fluid sampling. [1]

*Results that should not falsely reassure against drainage. [1][2][9][11][12]*

| Potentially reassuring finding | Why it can mislead | Correct next step |
| --- | --- | --- |
| Negative pleural-fluid culture [9] | Standard culture often fails to identify an organism in pleural infection. [9] | Follow pH, appearance, imaging, and clinical course; drain if other criteria are met. [9][11][12] |
| Pleural glucose above 60 mg/dL in diabetes [12] | Hyperglycemia can elevate pleural glucose despite infection. [12] | Prioritize immediate pH measurement and imaging findings. [2][12] |
| Normal or elevated pH [11] | Rare Proteus empyema may have elevated pH. [11] | If purulence, microbiology, loculation, or sepsis persists, pursue drainage and source control. [11][12] |
| CT unable to stage infection [1] | CT and ultrasound do not reliably distinguish empyema from parapneumonic effusion stage. [1] | Base drainage on fluid findings, loculation, collection size, and clinical trajectory. [1][2][12] |

## References
1. BTS guidelines for the management of pleural infection in children — thorax.bmj.com — https://thorax.bmj.com/content/60/suppl_1/i1
2. Online Appendix C2 BTS Guideline for Pleural Disease ... - Thorax — thorax.bmj.com — https://thorax.bmj.com/content/thoraxjnl/78/Suppl_3/s1/DC15/embed/inline-supplementary-material-15.pdf?download=true
3. Improving patient pathways for the investigation of pleural effusions — thorax.bmj.com — https://thorax.bmj.com/content/thoraxjnl/early/2020/03/26/thoraxjnl-2019-214309/DC1/embed/inline-supplementary-material-1.pdf?download=true
4. Intrapleural fibrinolysis and DNase versus video-assisted thoracic surgery (VATS) for the treatment of pleural empyema (FIVERVATS): protocol for a randomised, controlled trial – surgery as first-line treatment — bmjopen.bmj.com — https://bmjopen.bmj.com/content/12/3/e054236
5. Management of parapneumonic effusion and empyema : The Journal of Association of Chest Physicians — journals.lww.com — https://journals.lww.com/ascp/Fulltext/2019/07020/Management_of_parapneumonic_effusion_and_empyema.1.aspx
6. Management of parapneumonic pleural effusion in adults - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1579212915003158
7. Pharmacotherapy in complicated parapneumonic pleural effusions and thoracic empyema - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1094553904001609
8. Parapneumonic Effusion - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/veterinary-science-and-veterinary-medicine/parapneumonic-effusion
9. Role of interventional pulmonology in the management of complicated parapneumonic pleural effusions and empyema - Breen - 2014 - Respirology - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/resp.12339
10. Predicting Factors for Outcome of Tube Thoracostomy in Complicated Parapneumonic Effusion or Empyema - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S001236921635646X
11. The management of pleural space infections - Chapman - 2004 - Respirology - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/j.1440-1843.2003.00535.x
12. Distinguishing complicated from uncomplicated... : Current Opinion in Pulmonary Medicine — journals.lww.com — https://journals.lww.com/co-pulmonarymedicine/fulltext/2015/07000/distinguishing_complicated_from_uncomplicated.8.aspx?Ppt=Article%7Cco-pulmonarymedicine%3A2015%3A07000%3A00008%7C10.1097%2Fmcp.0000000000000164%7C
13. TSANZ Abstract - 2025 - Internal Medicine Journal - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/imj.70003
14. Intrapleural Fibrinolytic Therapy : Chest - Ovid — journals.lww.com — https://journals.lww.com/00002953-202602000-00012
15. 1268 : Critical Care Medicine — journals.lww.com — https://journals.lww.com/ccmjournal/abstract/2012/12001/1268__treatment_of_complicated_parapneumonic.1226.aspx
16. Intrapleural therapy in management of complicated parapneumonic effusions and empyema - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/22291507
17. Parapneumonic Pleural Effusions and Empyema Thoracis - StatPearls — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK534297
18. Pleural fluid chemical analysis in parapneumonic effusions: a meta-analysis - Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK66368
19. Conservative and Surgical Modalities in the Management of Pediatric Parapneumonic Effusion and Empyema — journal.chestnet.org — https://journal.chestnet.org/article/S0012-3692(23)00811-5/abstract
20. Lung Decortication - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK564375
21. [PDF] Fibrinolytic Therapy versus Medical Thoracoscopy for Treatment of ... — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/34/NCT03213834/Prot_SAP_003.pdf
22. Medical thoracoscopy combined with intrapleural injection of urokinase for treatment of pleural infection-a multicenter, prospective, randomized controlled study: study protocol - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11742517
23. Rethinking the Doses of Tissue Plasminogen Activator and Deoxyribonuclease Administrated Concurrently for Intrapleural Therapy for Complicated Pleural Effusion and Empyema — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6368361
24. Intrapleural Tissue Plasminogen Activator and Deoxyribonuclease for Pleural Infection. An Effective and Safe Alternative to Surgery — www.atsjournals.org — https://www.atsjournals.org/doi/10.1513/AnnalsATS.201407-329OC

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.